Share Name Share Symbol Market Type Share ISIN Share Description
Oxford Biomedica LSE:OXB London Ordinary Share GB0006648157 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 11.98p 11.90p 11.94p - - - 0 06:30:09
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 27.8 -20.3 -0.6 - 372.23

Oxford Biomedica (OXB) Latest News

More Oxford Biomedica News
Oxford Biomedica Takeover Rumours

Oxford Biomedica (OXB) Share Charts

1 Year Oxford Biomedica Chart

1 Year Oxford Biomedica Chart

1 Month Oxford Biomedica Chart

1 Month Oxford Biomedica Chart

Intraday Oxford Biomedica Chart

Intraday Oxford Biomedica Chart

Oxford Biomedica (OXB) Discussions and Chat

Oxford Biomedica (OXB) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2018-02-22 16:52:2511.9746,5005,565.96O
2018-02-22 16:35:1011.9859,1287,083.53UT
2018-02-22 16:29:0911.9422,7382,714.92AT
2018-02-22 16:29:0911.94125,13314,940.88AT
2018-02-22 16:29:0011.9450,0005,970.00AT
View all Oxford Biomedica trades in real-time

Oxford Biomedica (OXB) Top Chat Posts

DateSubject
22/2/2018
08:20
Oxford Biomedica Daily Update: Oxford Biomedica is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker OXB. The last closing price for Oxford Biomedica was 11.98p.
Oxford Biomedica has a 4 week average price of 9.75p and a 12 week average price of 8.75p.
The 1 year high share price is 12.30p while the 1 year low share price is currently 3.90p.
There are currently 3,107,069,042 shares in issue and the average daily traded volume is 7,472,810 shares. The market capitalisation of Oxford Biomedica is £372,226,871.23.
22/2/2018
13:14
luxsuspick: Breaking Down Oxford BioMedica PLC’s (LON:OXB) Ownership Structure Erna Eldridge February 22, 2018 I am going to take a deep dive into Oxford BioMedica PLC’s (LSE:OXB) most recent ownership structure, not a frequent subject of discussion among individual investors. Ownership structure has been found to have an impact on shareholder returns in both short- and long-term. Differences in ownership structure of companies can have a profound effect on how management’s incentives are aligned with shareholder returns, and whether they adhere to corporate governance best practices. Although this is an important factor for long-term investors, many investors can also be impacted by institutional presence and their high-volume trading. Therefore, I will take a look at OXB’s shareholders in more detail. Check out our latest analysis for Oxford BioMedica LSE:OXB Ownership_summary Feb 22nd 18 LSE:OXB Ownership_summary Feb 22nd 18 Institutional Ownership OXB’s 68.26% institutional ownership seems enough to cause large share price movements in the case of significant share sell-off or acquisitions by institutions, particularly when there is a low level of public shares available on the market to trade. These moves, at least in the short-term, are generally observed in an institutional ownership mix comprising of active stock pickers, in particular levered hedge funds, which can cause large price swings. With hedge funds holding a 18.72% stake in the company, its share price can experience heightened volatility. But I also examine other ownership types and their potential impact on OXB’s investment case. Insider Ownership Insiders form another group of important ownership types as they manage the company’s operations and decide the best use of capital. Insider ownership has been linked to better alignment between management and shareholders. Although individuals in OXB hold only a 3.79% stake, it’s a good sign for shareholders as the company’s executives and directors have their incentives directly linked to the company’s performance. In addition to this, it may be interesting to look at insider buying and selling activities. Keep in mind that buying may be sign of upbeat future expectations, but selling doesn’t necessarily mean the opposite as the insiders might just be doing it out of their personal financial needs. LSE:OXB Insider_trading Feb 22nd 18 LSE:OXB Insider_trading Feb 22nd 18 General Public Ownership With 6.23% ownership, the general public are also an important ownership class in OXB. This size of ownership, while considerably large for a public company, may not be enough to change company policy if the decision is not in sync with other large shareholders. Private Company Ownership Another group of owners that a potential investor in OXB should consider are private companies, with a stake of 2.82%. While they invest more often due to strategic interests, an investment can also be driven by capital gains through share price appreciation. However, an ownership of this size may be relatively insignificant, meaning that these shareholders may not have the potential to influence OXB’s business strategy. Thus, investors not need worry too much about the consequences of these holdings. Next Steps: I suggest investors seek some degree of margin of safety due to high institutional ownership in OXB, in particular due to the strong presence of active hedge fund investors. This may enable shareholders to comfortably invest in the company and avoid getting trapped in a sustained sell-off that is often observed in stocks with this level of institutional participation. However, if you are building an investment case for OXB, ownership structure alone should not dictate your decision to buy or sell the stock. Instead, you should be evaluating company-specific factors such as Oxford BioMedica’s past track record and financial health. I highly recommend you to complete your research by taking a look at the following: 1. Future Outlook: What are well-informed industry analysts predicting for OXB’s future growth? Take a look at our free research report of analyst consensus for OXB’s outlook. 2. Past Track Record: Has OXB been consistently performing well irrespective of the ups and downs in the market? Go into more detail in the past performance analysis and take a look at the free visual representations of OXB’s historicals for more clarity. 3. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here. NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures. Want to know why the market is moving
14/2/2018
15:57
old sage: Gareth Jones Don't know if there's ever a good time , to be a LTH (unless you got into OXB at circa 3 pence and are holding on for 30 pence. However with the future looking promising, anyone with an interest in OXB should, (as HST alluded to, earlier ) hang on in there. The prospects have never been better for the OXB share price, over the last two decades. GLA
05/12/2017
17:49
scrutable: There is such a dog fight over clinical details and egos on this board, that non technical people must have lost sight of the fundamentals which affect the OXB share price. It has exhibited an ever more dampened sideways oscillation and fails to reflect the great furore over the prospects for CAR-T therapy repeated in the global Press, Conferences and video broadcasting, since July. I am irritated by failing to be able to turn up an influential article in the European edition of the NY Times, quoting JD several times and OXB by name that I read a week or so ago. The gist was that authorisation to manufacture the virus vector in cell therapy is excrutiatingly difficult to earn, and that there is a currently irremediable shortage of the product putting OXB in a lead position with more potential drug developer clients than can be supplied for years. Only this can explain the fairly unusual contract they were able to close with Novartis. Would be purchasers are jostling each other for access to the few adequately structured suppliers Most of those who have tried to establish an in-house supply have wasted years and failed. One such company acquired a recipe and IP, but after 18 months had failed to produce anything at all of use due to a very small error controlling the exact acidity of the supply, which was killing the viral vector. There is no short cut to displacing OXB as a main supplier. The technology and process detail, and the control procedures, the staff trained and trusted to apply them, agreement details and signatures required cannot be established in under 2-3 years. So why have investors failed to take the basics of supply and demand into consideration.
13/9/2017
09:33
graham101: Thanks for the replies. I realise that the share price has gone up dramatically in the last year. However, when the Novartis FDA approval came through, I would have expected OXB share price to go even higher, which is why I bought in. It has dropped back quite a bit since then and that is what I can't understand. The other reason I bought is because I think the future use for the treatments is astounding if all goes to plan. Fortunately, I bought some KITE two weeks before the GILD take-over was announced so had a great return in a very short time. Just luck though. I really hope these treatments are successful as it could transform so many lives.
05/9/2017
12:08
prambigear: This news is not helping the Novartis or OXB share prices, it should because it lengthens the time where we have the market, but I guess investors do not know the difference between our CAR-T treatment and an allogeneic CAR-T. the_doctor does. But presumably he is doing something else....
13/7/2017
13:32
stocktastic: 'As for the IPO, a pet subject of yours, I can't think of a better example showing that when you raise something which is plainly tripe' Here is the basis for my speculation: - The OXB share price had risen phenomenally to 12p - Worldwide, there was a massive biotech IPO bubble going on, with the window wider than it has ever been - OXB was flagging how US listed comparators got much better valuations - OXB needed cash - OXB switched to Jeffries - a firm with great presence in the UK and EU as well as US - also one of the top firms for healthcare - Many of the directors all buying smallish sums around the same time at what were historically high price levels. No honest poster would call that 'tripe' So you just think it's a coincidence that most/all of the directors bought relatively small quantities of stock around the highs? You think OXB would be paying high rates of interest if they could have taken a rare opportunity to tap the US markets? Coincidence that OXB announced a fundraiser that included a private placing in the US, shortly after my IPO-failed speculation? My view on that was that they were making the most of parties that had become interested through a US listing attempt It's actually all quite plausible. Certainly no need to call it tripe
11/7/2017
13:01
stocktastic: 'revisionist history' eh? Nothing revised there 'I must remember that escape for future reference - claim the other person raised it first' You're perhaps misinterpreting as I didn't do that at all.. Re IPO theory - I just reiterated it is MY opinion, but asked whether OXB could confirm it to be wrong when I speculate they tried to list in the US Then I said that I disagree with your view that they'd not be able to afford a US listing - since as explained, half the purpose of listing would be to raise cash. So where's the 'escape' and claiming someone else raised it first??? Look at my US listing theory this way - The OXB share price had risen phenomenally to 12p - Worldwide, there was a massive biotech IPO bubble going on, with the window wider than it has ever been - OXB was flagging how US listed comparators got much better valuations - OXB needed cash - OXB switched to Jeffries - a firm with great presence in the UK and EU as well as US - also one of the top firms for healthcare - Many of the directors all buying smallish sums around the same time at what were historically high price levels. So you're suggesting that the company took on loans at a high rate of interest rather than try and capitalise on a rare opportunity to list in the US on great terms? It actually seems rather unlikely to me that OXB didn't try to list in the US IMO the reason the company failed was the early stage of products, the past failures and the lower appetite for manufacturing/royalies vs more traditional biotech listings etc.
06/7/2017
13:28
asat91: As I understand it, OXB are spending £40mill per year at the moment, and their revenue is about 20-30mill without CTL019. So if they make the £65mill/year estimated from CTL019, and maintain their current revenue and costs this would give a pre-tax profit of about £40mill/year. Earnings per share in that situation would be 40mill/3billion = 0.013. P/E ratio at current share price would be 7.5, which as marcus says would be very low for a promising biotech company in oncology gene therapy, especially a biotech company that is so valuable to a giant like Novartis. Expect a P/E ratio of between 15 and 25 by December 2017 or by December 2018 when they release their profits (assuming approval and sales of CTL019) which would give a share price of 25p+. Better investment than any bank account that's for sure! Even if we will have to wait until Dec 18 for the profit statement after CTL019 has been selling a while. And of course with good news coverage, positive broker reports and popularity comes market hysteria which could even push the share price up to something ridiculous like 40p or 50p at some point next year. I wasn't around for Trovax but I assume that's what happened there? If Novartis do decide to buy/acquire OXB at some point over the next year or two, we could be looking at a sale price of close to £1billion which Novartis can easily afford with cash reserves of £14billion+, and would be more than 3x current OXB share price. What do you guys think?
02/7/2017
17:54
gareth jones: I fear for the OXB share price in the morning given all this good news! Seriously we should see good volume and hopefully a positive share price leading up to the FDA meeting on 12th. If we dont get an announcement/decision on 12th we may see a draw back as short termers have to bail out but it should make little difference to all LTH's. MM's will earn their money in the next couple of weeks as they respond to market sentiment and demand in setting buy/sell prices.
22/1/2017
01:10
beanol: HarryFrom reading your always thoughtful and considered posts for years I know you have a deep well of understanding about Oxb which the rest of us profit from and I certainly for one will never rival or come near. But right now (2017) there's a business imperative on the march - Novartis and Car T therapy : I am clear from a combination of the following: letter LT wrote following two specific complaints I made, speaking to people connected to Novartis, others involved in the haplessly managed fund raising last year that this year if not now or never for Oxb will certainly be pretty critical for the company. No substantive progress for Novartis no progression for Oxb share price. But if progress for Novartis and Car T then we get into a virtuous circle which will per force mean a closer relationship or more with Novartis. Given what the latter have riding on Car T there is likely to be no other alternative. I can't believe Trovax or any other drug from Oxb's stable will (really) come into the reckoning. Time will tell obviously but let's see where we are end of April. In writing this I realise I am becoming a one trick pony but in spite of its pretensions to wider success so I'm afraid Oxb may be becoming too.
Oxford Biomedica share price data is direct from the London Stock Exchange
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:30 V: D:20180223 08:09:38